Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels
BackgroundPD-1 inhibitors have shown promising efficacy in enhancing OS and AEs as second-line therapies for patients with advanced esophageal squamous cell carcinoma (ESCC). However, there remains no clear consensus on which PD-1 inhibitor provides the best balance between efficacy and safety. To a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510145/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590833105240064 |
|---|---|
| author | Fei Yang Min Dan Jindan Shi Ling Fan Haoluo Zhang Tiantian Jian Kelu Lei Yue Wang Juan Xin Zhigang Yu Wei Chen |
| author_facet | Fei Yang Min Dan Jindan Shi Ling Fan Haoluo Zhang Tiantian Jian Kelu Lei Yue Wang Juan Xin Zhigang Yu Wei Chen |
| author_sort | Fei Yang |
| collection | DOAJ |
| description | BackgroundPD-1 inhibitors have shown promising efficacy in enhancing OS and AEs as second-line therapies for patients with advanced esophageal squamous cell carcinoma (ESCC). However, there remains no clear consensus on which PD-1 inhibitor provides the best balance between efficacy and safety. To address this key issue in the second-line treatment of ESCC, we conducted a network meta-analysis (NMA) with a focus on OS benefits, particularly in patients with different levels of PD-L1 expression.MethodsA systematic search of relevant literature was conducted in Web of Science, Embase, PubMed, and Cochrane Library, covering publications from the inception of these database to June 2024. The evaluated endpoints included OS, progression-free survival (PFS), objective response rate (ORR), AEs, and Grade ≥ 3 adverse events (Grade ≥ 3 AEs). A systematic review and Bayesian network meta-analysis were performed to assess the efficacy and safety of various immunotherapy regimens in patients with advanced ESCC. To ensure transparency, novelty, and reliability, this study was prospectively registered in the systematic review registry (CRD42024540581).ResultsFive randomized controlled trials (RCTs), encompassing 2,078 patients and six treatment regimens, were included in this study. Among advanced ESCC patients not selected based on PD-L1 expression, Sintilimab demonstrated the greatest OS benefit (HR = 0.70, 95% CI: 0.50-0.98). Camrelizumab showed the most favorable improvement in PFS compared to chemotherapy (HR = 0.64, 95% CI: 0.47-0.87) and also achieved the best ORR benefit (OR = 3.72, 95% CI: 1.98-6.99). In terms of safety, Nivolumab (OR = 0.10, 95% CI: 0.05-0.19) and Tislelizumab (OR = 0.18, 95% CI: 0.10-0.33) exhibited significant safety advantages over chemotherapy concerning AEs. Moreover, Nivolumab (OR = 0.13, 95% CI: 0.08-0.20) was associated with a markedly lower risk of Grade ≥ 3 AEs compared to chemotherapy. Subgroup analysis based on PD-L1 expression revealed that Tislelizumab (HR = 0.53, 95% CI: 0.37-0.76) offered the greatest OS benefit for patients with PD-L1 ≥ 10%, while Camrelizumab (HR = 0.71, 95% CI: 0.57-0.89) was the most likely regimen to provide an OS advantage for patients with PD-L1 < 10%.ConclusionCompared to chemotherapy, PD-1 inhibitors may provide improved survival outcomes for patients with advanced ESCC. Among patients not selected based on PD-L1 expression, Sintilimab is most likely to deliver the best survival benefit. For patients with PD-L1 expression ≥ 10%, Tislelizumab is expected to offer the greatest efficacy, while Camrelizumab appears to be the most effective for those with PD-L1 < 10%.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024540581. |
| format | Article |
| id | doaj-art-a06d5bb450b44c9da0e443954de9df80 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-a06d5bb450b44c9da0e443954de9df802025-01-23T06:56:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-01-011510.3389/fimmu.2024.15101451510145Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levelsFei Yang0Min Dan1Jindan Shi2Ling Fan3Haoluo Zhang4Tiantian Jian5Kelu Lei6Yue Wang7Juan Xin8Zhigang Yu9Wei Chen10Department of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Ya ‘an People’s Hospital, Ya ‘an, ChinaDepartment of Pharmacy, Emergency General Hospital, Beijing, ChinaBackgroundPD-1 inhibitors have shown promising efficacy in enhancing OS and AEs as second-line therapies for patients with advanced esophageal squamous cell carcinoma (ESCC). However, there remains no clear consensus on which PD-1 inhibitor provides the best balance between efficacy and safety. To address this key issue in the second-line treatment of ESCC, we conducted a network meta-analysis (NMA) with a focus on OS benefits, particularly in patients with different levels of PD-L1 expression.MethodsA systematic search of relevant literature was conducted in Web of Science, Embase, PubMed, and Cochrane Library, covering publications from the inception of these database to June 2024. The evaluated endpoints included OS, progression-free survival (PFS), objective response rate (ORR), AEs, and Grade ≥ 3 adverse events (Grade ≥ 3 AEs). A systematic review and Bayesian network meta-analysis were performed to assess the efficacy and safety of various immunotherapy regimens in patients with advanced ESCC. To ensure transparency, novelty, and reliability, this study was prospectively registered in the systematic review registry (CRD42024540581).ResultsFive randomized controlled trials (RCTs), encompassing 2,078 patients and six treatment regimens, were included in this study. Among advanced ESCC patients not selected based on PD-L1 expression, Sintilimab demonstrated the greatest OS benefit (HR = 0.70, 95% CI: 0.50-0.98). Camrelizumab showed the most favorable improvement in PFS compared to chemotherapy (HR = 0.64, 95% CI: 0.47-0.87) and also achieved the best ORR benefit (OR = 3.72, 95% CI: 1.98-6.99). In terms of safety, Nivolumab (OR = 0.10, 95% CI: 0.05-0.19) and Tislelizumab (OR = 0.18, 95% CI: 0.10-0.33) exhibited significant safety advantages over chemotherapy concerning AEs. Moreover, Nivolumab (OR = 0.13, 95% CI: 0.08-0.20) was associated with a markedly lower risk of Grade ≥ 3 AEs compared to chemotherapy. Subgroup analysis based on PD-L1 expression revealed that Tislelizumab (HR = 0.53, 95% CI: 0.37-0.76) offered the greatest OS benefit for patients with PD-L1 ≥ 10%, while Camrelizumab (HR = 0.71, 95% CI: 0.57-0.89) was the most likely regimen to provide an OS advantage for patients with PD-L1 < 10%.ConclusionCompared to chemotherapy, PD-1 inhibitors may provide improved survival outcomes for patients with advanced ESCC. Among patients not selected based on PD-L1 expression, Sintilimab is most likely to deliver the best survival benefit. For patients with PD-L1 expression ≥ 10%, Tislelizumab is expected to offer the greatest efficacy, while Camrelizumab appears to be the most effective for those with PD-L1 < 10%.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024540581.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510145/fullesophageal squamous cell carcinoma (ESCC)immune checkpoint inhibitors (ICIs)network meta-analysisefficacysafety |
| spellingShingle | Fei Yang Min Dan Jindan Shi Ling Fan Haoluo Zhang Tiantian Jian Kelu Lei Yue Wang Juan Xin Zhigang Yu Wei Chen Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels Frontiers in Immunology esophageal squamous cell carcinoma (ESCC) immune checkpoint inhibitors (ICIs) network meta-analysis efficacy safety |
| title | Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels |
| title_full | Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels |
| title_fullStr | Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels |
| title_full_unstemmed | Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels |
| title_short | Efficacy and safety of PD-1 inhibitors as second-line treatment for advanced squamous esophageal cancer: a systematic review and network meta-analysis with a focus on PD-L1 expression levels |
| title_sort | efficacy and safety of pd 1 inhibitors as second line treatment for advanced squamous esophageal cancer a systematic review and network meta analysis with a focus on pd l1 expression levels |
| topic | esophageal squamous cell carcinoma (ESCC) immune checkpoint inhibitors (ICIs) network meta-analysis efficacy safety |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1510145/full |
| work_keys_str_mv | AT feiyang efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT mindan efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT jindanshi efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT lingfan efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT haoluozhang efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT tiantianjian efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT kelulei efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT yuewang efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT juanxin efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT zhigangyu efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels AT weichen efficacyandsafetyofpd1inhibitorsassecondlinetreatmentforadvancedsquamousesophagealcancerasystematicreviewandnetworkmetaanalysiswithafocusonpdl1expressionlevels |